Melanoma Institute Australia

This study looks at whether adding targeted radiation to the brain (stereotactic radiotherapy) to standard immunotherapy drugs (ipilimumab and nivolumab) helps people with melanoma that has spread to the brain. About 218 adults with stage IV melanoma and untreated brain tumors wi…

This study tests new combinations of immunotherapy drugs given before surgery for people with advanced melanoma that is hard to treat. The goal is to see if these combinations can shrink or eliminate the tumor before it is removed, reducing the chance of the cancer coming back. A…

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can improve outcomes for people with stage I to III Merkel cell carcinoma, a rare skin cancer. About 20 adults with resectable tumors will receive the drugs for six weeks, then have …

This study tests whether removing only the largest affected lymph node (index node) is as good as removing all lymph nodes in the area for stage III melanoma. After 6 weeks of standard immunotherapy, 1500 participants will be randomly assigned to one of the two surgeries. The goa…

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can shrink advanced skin cancer (cutaneous squamous cell carcinoma) and lower the chance of it coming back. About 20 adults with stage II to IV cancer that can be removed will receiv…

This study looks at whether adding a precise type of radiation (SBRT) to standard immunotherapy can help people with advanced melanoma that has spread to a few places in the body. About 129 adults with untreated, stage IV melanoma that cannot be removed by surgery will be randoml…

This study is testing a new tool that predicts whether immunotherapy will work for people with melanoma and other skin cancers. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants and compare the tool's predictions to actual treatment outcomes.…